Oculis nabs $20.3 mln Series B
Oculis, a Swiss developer of ophthalmic drugs, has raised $20.3 million in Series B funding. The investors included Bay City Capital, Novartis Venture Fund, Pivotal bioVenture Partners, Brunnur Ventures and Silfurberg.
4 January 2018•4 mins read
